Cosmos Health (NASDAQ:COSM – Get Free Report) and NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
Profitability
This table compares Cosmos Health and NewAmsterdam Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cosmos Health | -30.41% | -52.85% | -17.87% |
| NewAmsterdam Pharma | -943.23% | -26.49% | -24.37% |
Risk and Volatility
Cosmos Health has a beta of 4.79, meaning that its share price is 379% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cosmos Health | $65.27 million | 0.16 | -$19.15 million | ($0.64) | -0.27 |
| NewAmsterdam Pharma | $22.50 million | 172.70 | -$203.82 million | ($1.79) | -18.57 |
Cosmos Health has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
12.6% of Cosmos Health shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 26.2% of Cosmos Health shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings for Cosmos Health and NewAmsterdam Pharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cosmos Health | 1 | 0 | 0 | 0 | 1.00 |
| NewAmsterdam Pharma | 1 | 1 | 9 | 1 | 2.83 |
NewAmsterdam Pharma has a consensus price target of $48.60, indicating a potential upside of 46.21%. Given NewAmsterdam Pharma’s stronger consensus rating and higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Cosmos Health.
Summary
Cosmos Health beats NewAmsterdam Pharma on 8 of the 15 factors compared between the two stocks.
About Cosmos Health
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Receive News & Ratings for Cosmos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmos Health and related companies with MarketBeat.com's FREE daily email newsletter.
